Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/33

May 21, 2025

To The Manager, **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	**Scrip Symbol - BIOCON**

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **"Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan".**

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

SIDDHARTH MITTAL
Digitally signed by SIDDHARTH MITTAL
Date: 2025.05.21 07:59:05 +05'30'

Siddharth Mittal
Managing Director & CEO
DIN: 03230757

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan

Bengaluru, Karnataka, India, May 21, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that its commercial partner in Japan, Yoshindo Inc., has launched **Ustekinumab BS Subcutaneous Injection [YD]**, a biosimilar to the reference product Stelara® (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment of **psoriasis vulgaris** and **psoriatic arthritis (PsA)**.

In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to **commercialize Ustekinumab in Japan** upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the **Pharmaceuticals and Medical Devices Agency (PMDA)** of Japan in December 2024**.**

Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions.

– Company Spokesperson